Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options 

BOZEMAN, Mont. – Sep. 26, 2023 – Golden Helix, Inc. announced that it was awarded the NIH SBIR Grant 1R43HG013456-01 “Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options.” 

Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice, dosage, efficacy, and safety for individual patients. The NIH SBIR grant allows Golden Helix to research pharmacogenetics analytics capabilities as an integrated component of NGS-based genetic testing.

The ultimate goal is to move away from “one drug fits all” or “one dose fits all” strategies. The PI of this grant, Dr. Scherer, President and CEO of Golden Helix, says, “Our long-term goal is to support healthcare providers to enhance clinical outcomes, reduce adverse drug reactions, and achieve cost-effective healthcare by integrating pharmacogenomics into routine clinical practice. We appreciate the support of the NIH in this endeavor.” 

This award marks an important step toward expanding precision medicine capabilities and equipping clinicians with actionable insights to guide treatment decisions. As Golden Helix continues to build out its PGx solutions, the company remains focused on delivering high-quality, clinically relevant tools that support scalable and cost-effective implementation in healthcare settings.

To learn more about this initiative or discuss collaboration opportunities, contact our team at [email protected].